Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure
| Autor: | Joseph G. Pigeon, Mary B. Fisher, Alvan R. Feinstein |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
medicine.medical_specialty
Captopril Heart disease Angiotensin-Converting Enzyme Inhibitors Placebo Random Allocation Double-Blind Method Enalapril Quality of life Lisinopril Internal medicine medicine Humans In patient Fatigue Heart Failure business.industry medicine.disease Distress Dyspnea Heart failure Quality of Life Cardiology Physical therapy Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | The American Journal of Cardiology. 64:50-55 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/0002-9149(89)90652-8 |
| Popis: | A new clinical index of dyspnea and fatigue has been applied to rate the condition of patients with congestive heart failure. The index has 3 components, each rated on a scale from 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component are added to form an aggregated score, which can range from 0, for the worst condition, to 12, for the best. Because dyspnea and fatigue are prime symptoms and sources of clinical distress, the index helps reflect the quality of life in patients with congestive heart failure. In double-blind trials of therapy, changes in the index showed good correlations with patients' self-selected ratings of improvement. The posttherapeutic changes in the index ratings were significantly higher with a new active agent (lisinopril) than with placebo or another active agent (captopril). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|